RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers

Nature Medicine

Volumn 22, Issue 8, 2016, Pages 933-939

  Nolan, Emma ^a,b   Vaillant, François ^a,b   Branstetter, Daniel ^c,g   Pal, Bhupinder ^a,b   Giner, Göknur ^a,b   Whitehead, Lachlan ^a   Lok, Sheau W ^a,d   Mann, Gregory B ^b,e   Rohrbach, Kathy ^c   Huang, Li Ya ^c   Soriano, Rosalia ^c   Smyth, Gordon K ^a,b   Dougall, William C ^c,h   Visvader, Jane E ^c   Lindeman, Geoffrey J ^a,b,d,f  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c AMGEN INC   (United States)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

^e ROYAL WOMEN'S HOSPITAL   (Australia)

^f Melbourne Comprehensive Cancer Centre   (Australia)

^g Cynosure Clinical Research LLC   (United States)

^h QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; BONE DENSITY CONSERVATION AGENT; BRCA1 PROTEIN, HUMAN; BRCA1 PROTEIN, MOUSE; PILOCARPIC ACID; PILOCARPINE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST CARCINOGENESIS; BREAST REDUCTION; CANCER PREVENTION; CANCER SURGERY; CELL PROLIFERATION; CONTROLLED STUDY; DNA REPAIR; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RNA SEQUENCE; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST; BREAST NEOPLASMS; CANCER TRANSPLANTATION; CARCINOGENESIS; CYTOPLASM; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; FLOW CYTOMETRY; GENETICS; HETEROZYGOTE; IMMUNOHISTOCHEMISTRY; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; PROPHYLACTIC MASTECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BRCA1 PROTEIN; BREAST; BREAST NEOPLASMS; CARCINOGENESIS; CELL PROLIFERATION; DENOSUMAB; DISEASE MODELS, ANIMAL; DNA REPAIR; FEMALE; FLOW CYTOMETRY; HETEROZYGOTE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM TRANSPLANTATION; ORGANOIDS; PILOCARPINE; PROPHYLACTIC MASTECTOMY; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STEM CELLS; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84975295506     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4118     Document Type: Article

References (54)

1. Lim, E. et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1-mutation carriers. Nat. Med. 15, 907-913 (2009).
2. King, T.A. et al. Increased progesterone receptor expression in benign epithelium of BRCA1-related breast cancers. Cancer Res. 64, 5051-5053 (2004).
3. Ma, Y. et al. The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells. Mol. Endocrinol. 20, 14-34 (2006).
4. Poole, A.J. et al. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314, 1467-1470 (2006).
5. Widschwendter, M. et al. The sex hormone system in carriers of BRCA1/2 mutations: a case-control study. Lancet Oncol. 14, 1226-1232 (2013).
6. Asselin-Labat, M.L. et al. Control of mammary stem cell function by steroid hormone signaling. Nature 465, 798-802 (2010).
7. Beleut, M. et al. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc. Natl. Acad. Sci. USA 107, 2989-2994 (2010).
8. Fernandez-Valdivia, R. & Lydon, J.P. From the ranks of mammary progesterone mediators, RANKL takes the spotlight. Mol. Cell. Endocrinol. 357, 91-100 (2012).
9. Joshi, P.A. et al. Progesterone induces adult mammary stem cell expansion. Nature 465, 803-807 (2010).
10. Tanos, T. et al. Progesterone-RANKL is a major regulatory axis in the human breast. Sci. Transl. Med. 5, 182ra55 (2013).
11. Gonzalez-Suarez, E. et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468, 103-107 (2010).
12. Schramek, D. et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468, 98-102 (2010).
13. Pellegrini, P. et al. Constitutive activation of RANK disrupts mammary cell fate leading to tumorigenesis. Stem Cells 31, 1954-1965 (2013).
14. Antoniou, A. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 72, 1117-1130 (2003).
15. Perou, C.M. et al. Molecular portraits of human breast tumors. Nature 406, 747-752 (2000).
16. Turner, N., Tutt, A. & Ashworth, A. Hallmarks of 'BRCAness' in sporadic cancers. Nat. Rev. Cancer 4, 814-819 (2004).
17. Venkitaraman, A.R. Cancer suppression by the chromosome custodians, BRCA1 and BRCA2. Science 343, 1470-1475 (2014).
18. Narod, S.A. & Foulkes, W.D. BRCA1 and BRCA2: 1994 and beyond. Nat. Rev. Cancer 4, 665-676 (2004).
19. Molyneux, G. et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 7, 403-417 (2010).
20. Proia, T.A. et al. Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. Cell Stem Cell 8, 149-163 (2011).
21. Joshi, P.A. et al. RANK signaling amplifies WNT-responsive mammary progenitors through R-SPONDIN1. Stem Cell Rep. 5, 31-44 (2015).
22. Pal, B. et al. Global changes in the mammary epigenome are induced by hormonal cues and coordinated by Ezh2. Cell Rep. 3, 411-426 (2013).
23. Eirew, P. et al. A method for quantifying normal human mammary epithelial stem cells with in vivo regenerative ability. Nat. Med. 14, 1384-1389 (2008).
24. Eirew, P. et al. Aldehyde dehydrogenase activity is a biomarker of primitive normal human mammary luminal cells. Stem Cells 30, 344-348 (2012).
25. Liu, S. et al. BRCA1 regulates human mammary stem-progenitor cell fate. Proc. Natl. Acad. Sci. USA 105, 1680-1685 (2008).
26. Wood, C.E. et al. Progestin effects on cell proliferation pathways in the postmenopausal mammary gland. Breast Cancer Res. 15, R62 (2013).
27. Pathania, S. et al. BRCA1 haploinsufficiency for replication-stress suppression in primary cells. Nat. Commun. 5, 5496 (2014).
28. Sedic, M. et al. Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature senescence. Nat. Commun. 6, 7505 (2015).
29. Kostenuik, P.J. et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine-human) RANKL. J. Bone Miner. Res. 24, 182-195 (2009).
30. Shackleton, M. et al. Generation of a functional mammary gland from a single stem cell. Nature 439, 84-88 (2006).
31. Shehata, M. et al. Phenotypic and functional characterization of the luminal cell hierarchy of the mammary gland. Breast Cancer Res. 14, R134 (2012).
32. Liu, X. et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc. Natl. Acad. Sci. USA 104, 12111-12116 (2007).
33. Fu, N.Y. et al. EGF-mediated induction of Mcl-1 at the switch to lactation is essential for alveolar cell survival. Nat. Cell Biol. 17, 365-375 (2015).
34. Hartmann, L.C. & Lindor, N.M. The role of risk-reducing surgery in hereditary breast and ovarian cancer. N. Engl. J. Med. 374, 454-468 (2016).
35. Phillips, K.A. & Lindeman, G.J. Breast cancer prevention for BRCA1- and BRCA-mutation carriers: is there a role for tamoxifen? Future Oncol. 10, 499-502 (2014).
36. Domchek, S.M. et al. Association of risk-reducing surgery in BRCA1- or BRCA2-mutation carriers with cancer risk and mortality. J. Am. Med. Assoc. 304, 967-975 (2010).
37. Rebbeck, T.R. et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346, 1616-1622 (2002).
38. Heemskerk-Gerritsen, B.A. et al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2-mutation carriers: revisiting the evidence for risk reduction. J. Natl. Cancer Inst. 107, djv033 (2015).
39. To, C. et al. The PARP inhibitors veliparib and olaparib are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice. Cancer Prev. Res. (Phila.) 7, 698-707 (2014).
40. Gnant, M. et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicenter, randomized, double-blind, placebo-controlled trial. Lancet 386, 433-443 (2015).
41. Mann, G.J. et al. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res. 8, R12 (2006).
42. Branstetter, D.G. et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin. Cancer Res. 18, 4415-4424 (2012).
43. Wagner, K.U. et al. Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res. 25, 4323-4330 (1997).
44. Xu, X. et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumor formation. Nat. Genet. 22, 37-43 (1999).
45. Jacks, T. et al. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4, 1-7 (1994).
46. Oakes, S.R. et al. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proc. Natl. Acad. Sci. USA 109, 2766-2771 (2012).
47. Liao, Y., Smyth, G.K. & Shi, W. The Subread aligner: fast, accurate and scalable read-mapping by seed-and-vote. Nucleic Acids Res. 41, e108 (2013).
48. Liao, Y., Smyth, G.K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923-930 (2014).
49. Robinson, M.D. & Oshlack, A. A scaling-normalization method for differential expression analysis of RNA-seq data. Genome Biol. 11, R25 (2010).
50. Ritchie, M.E. et al. limma powers differential expression analyses for RNA sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
51. Law, C.W., Chen, Y., Shi, W. & Smyth, G.K. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 15, R29 (2014).
52. Smyth, G.K. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, e3 (2004).
53. Robinson, M.D., McCarthy, D.J. & Smyth, G.K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139-140 (2010).
54. Wu, D. et al. ROAST: rotation gene set tests for complex microarray experiments. Bioinformatics 26, 2176-2182 (2010).